Alpha Fusion, a radiopharmaceutical venture, and Curadh MTR, a clinical-stage biopharma company, have announced a strategic partnership focused on the development of Astatine-211 (At-211) based targeted alpha therapies. The collaboration aims to accelerate the advancement of next-generation treatments for hard-to-treat cancers.
Advancing Targeted Alpha Therapy
Astatine-211 is a promising alpha-emitting radioisotope with potential to deliver highly selective and potent radiotherapy to cancer cells, while minimizing damage to surrounding healthy tissue. Through this partnership:
-
Alpha Fusion will provide At-211 production and supply capabilities.
-
Curadh MTR will lead the clinical development of novel At-211-based drug candidates.
-
Both companies will co-develop infrastructure to support future commercialization.
Supporting Precision Oncology
This alliance aligns with global efforts to expand access to precision radiopharmaceuticals and develop safer, more effective oncology treatments. The partnership also aims to advance regulatory pathways for At-211 therapies in multiple markets.
Executive Commentary
A spokesperson from Alpha Fusion stated:
“Our collaboration with Curadh MTR brings complementary strengths to the table, accelerating the pipeline for breakthrough alpha therapies.”
Curadh MTR added:
“This partnership enhances our ability to deliver next-generation radiotherapeutics that can make a meaningful difference for patients with difficult-to-treat cancers.”
👉 Read the full analysis at- Alpha Fusion, Curadh MTR Partner on Astatine-211 Drugs
👉 Subscribe us IT Business Today
Comments
0 comment